Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 75

1.

Oral non-steroidal anti-inflammatory drug therapy for lung disease in cystic fibrosis.

Lands LC, Stanojevic S.

Cochrane Database Syst Rev. 2019 Sep 9;9:CD001505. doi: 10.1002/14651858.CD001505.pub5.

PMID:
31499593
2.

Computer and mobile technology interventions to promote medication adherence and disease management in people with thalassemia.

Badawy SM, Morrone K, Thompson A, Palermo TM.

Cochrane Database Syst Rev. 2019 Jun 28;6:CD012900. doi: 10.1002/14651858.CD012900.pub2. Review.

PMID:
31250923
3.

Spotlight on inhaled ciprofloxacin and its potential in the treatment of non-cystic fibrosis bronchiectasis.

Chorepsima S, Kechagias KS, Kalimeris G, Triarides NA, Falagas ME.

Drug Des Devel Ther. 2018 Nov 27;12:4059-4066. doi: 10.2147/DDDT.S168014. eCollection 2018. Review.

4.

Impact of Long-Term Erythromycin Therapy on the Oropharyngeal Microbiome and Resistance Gene Reservoir in Non-Cystic Fibrosis Bronchiectasis.

Choo JM, Abell GCJ, Thomson R, Morgan L, Waterer G, Gordon DL, Taylor SL, Leong LEX, Wesselingh SL, Burr LD, Rogers GB.

mSphere. 2018 Apr 18;3(2). pii: e00103-18. doi: 10.1128/mSphere.00103-18. Print 2018 Apr 25.

5.

High-dose vitamin D in Addison's disease regulates T-cells and monocytes: A pilot trial.

Penna-Martinez M, Filmann N, Bogdanou D, Shoghi F, Huenecke S, Schubert R, Herrmann E, Koehl U, Husebye ES, Badenhoop K.

Nutrition. 2018 May;49:66-73. doi: 10.1016/j.nut.2017.10.021. Epub 2017 Dec 2.

PMID:
29522979
6.

Enzyme replacement therapy for infantile-onset Pompe disease.

Chen M, Zhang L, Quan S.

Cochrane Database Syst Rev. 2017 Nov 20;11:CD011539. doi: 10.1002/14651858.CD011539.pub2. Review.

7.

Splenectomy versus conservative management for acute sequestration crises in people with sickle cell disease.

Owusu-Ofori S, Remmington T.

Cochrane Database Syst Rev. 2017 Nov 7;11:CD003425. doi: 10.1002/14651858.CD003425.pub4. Review.

8.

Tezacaftor-Ivacaftor in Residual-Function Heterozygotes with Cystic Fibrosis.

Rowe SM, Daines C, Ringshausen FC, Kerem E, Wilson J, Tullis E, Nair N, Simard C, Han L, Ingenito EP, McKee C, Lekstrom-Himes J, Davies JC.

N Engl J Med. 2017 Nov 23;377(21):2024-2035. doi: 10.1056/NEJMoa1709847. Epub 2017 Nov 3.

9.

Antibiotic exposure and interpersonal variance mask the effect of ivacaftor on respiratory microbiota composition.

Peleg AY, Choo JM, Langan KM, Edgeworth D, Keating D, Wilson J, Rogers GB, Kotsimbos T.

J Cyst Fibros. 2018 Jan;17(1):50-56. doi: 10.1016/j.jcf.2017.08.002. Epub 2017 Oct 15.

PMID:
29042177
10.

Bypassing agent prophylaxis in people with hemophilia A or B with inhibitors.

Chai-Adisaksopha C, Nevitt SJ, Simpson ML, Janbain M, Konkle BA.

Cochrane Database Syst Rev. 2017 Sep 25;9:CD011441. doi: 10.1002/14651858.CD011441.pub2. Review.

11.

Rituximab for treating inhibitors in people with inherited severe hemophilia.

Jiang L, Liu Y, Zhang L, Santoro C, Rodriguez A.

Cochrane Database Syst Rev. 2017 Jul 7;7:CD010810. doi: 10.1002/14651858.CD010810.pub3. Review.

12.

Improvement in exercise duration, lung function and well-being in G551D-cystic fibrosis patients: a double-blind, placebo-controlled, randomized, cross-over study with ivacaftor treatment.

Edgeworth D, Keating D, Ellis M, Button B, Williams E, Clark D, Tierney A, Heritier S, Kotsimbos T, Wilson J.

Clin Sci (Lond). 2017 Jul 16;131(15):2037-2045. doi: 10.1042/CS20170995. Print 2017 Aug 1.

PMID:
28611235
14.

Digitoxin for Airway Inflammation in Cystic Fibrosis: Preliminary Assessment of Safety, Pharmacokinetics, and Dose Finding.

Zeitlin PL, Diener-West M, Callahan KA, Lee S, Talbot CC Jr, Pollard B, Boyle MP, Lechtzin N.

Ann Am Thorac Soc. 2017 Feb;14(2):220-229. doi: 10.1513/AnnalsATS.201608-649OC.

15.

Exercise for haemophilia.

Strike K, Mulder K, Michael R.

Cochrane Database Syst Rev. 2016 Dec 19;12:CD011180. doi: 10.1002/14651858.CD011180.pub2. Review.

16.

Treatment for avascular necrosis of bone in people with sickle cell disease.

Martí-Carvajal AJ, Solà I, Agreda-Pérez LH.

Cochrane Database Syst Rev. 2016 Aug 9;(8):CD004344. doi: 10.1002/14651858.CD004344.pub6. Review.

PMID:
27502327
17.

β2-Adrenergic receptor agonists activate CFTR in intestinal organoids and subjects with cystic fibrosis.

Vijftigschild LA, Berkers G, Dekkers JF, Zomer-van Ommen DD, Matthes E, Kruisselbrink E, Vonk A, Hensen CE, Heida-Michel S, Geerdink M, Janssens HM, van de Graaf EA, Bronsveld I, de Winter-de Groot KM, Majoor CJ, Heijerman HG, de Jonge HR, Hanrahan JW, van der Ent CK, Beekman JM.

Eur Respir J. 2016 Sep;48(3):768-79. doi: 10.1183/13993003.01661-2015. Epub 2016 Jul 28.

18.

Macrolide Treatment Inhibits Pseudomonas aeruginosa Quorum Sensing in Non-Cystic Fibrosis Bronchiectasis. An Analysis from the Bronchiectasis and Low-Dose Erythromycin Study Trial.

Burr LD, Rogers GB, Chen AC, Hamilton BR, Pool GF, Taylor SL, Venter D, Bowler SD, Biga S, McGuckin MA.

Ann Am Thorac Soc. 2016 Oct;13(10):1697-1703.

PMID:
27464029
19.

Enzyme replacement therapy for Anderson-Fabry disease.

El Dib R, Gomaa H, Carvalho RP, Camargo SE, Bazan R, Barretti P, Barreto FC.

Cochrane Database Syst Rev. 2016 Jul 25;7:CD006663. doi: 10.1002/14651858.CD006663.pub4. Review.

20.

Insulin and oral agents for managing cystic fibrosis-related diabetes.

Onady GM, Stolfi A.

Cochrane Database Syst Rev. 2016 Apr 18;4:CD004730. doi: 10.1002/14651858.CD004730.pub4. Review.

PMID:
27087121

Supplemental Content

Loading ...
Support Center